Log in

OTCMKTS:ARTHArch Therapeutics Stock Price, Forecast & News

$0.20
-0.02 (-8.49 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.20
Now: $0.20
$0.22
50-Day Range
$0.18
MA: $0.20
$0.23
52-Week Range
$0.12
Now: $0.20
$0.38
Volume410,565 shs
Average Volume274,567 shs
Market Capitalization$37.29 million
P/E RatioN/A
Dividend YieldN/A
Beta0.2
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Read More
Arch Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARTH
Previous SymbolNASDAQ:ARTH
CUSIPN/A
Phone617-431-2313

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-4,550,000.00

Miscellaneous

Employees8
Market Cap$37.29 million
Next Earnings Date8/6/2020 (Estimated)
OptionableNot Optionable

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

How has Arch Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Arch Therapeutics' stock was trading at $0.2050 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARTH shares have decreased by 2.7% and is now trading at $0.1995. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arch Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arch Therapeutics.

When is Arch Therapeutics' next earnings date?

Arch Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Arch Therapeutics.

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics Inc (OTCMKTS:ARTH) posted its quarterly earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.01). View Arch Therapeutics' earnings history.

What price target have analysts set for ARTH?

2 analysts have issued 1 year price targets for Arch Therapeutics' stock. Their forecasts range from $1.25 to $2.00. On average, they expect Arch Therapeutics' share price to reach $1.63 in the next year. This suggests a possible upside of 714.5% from the stock's current price. View analysts' price targets for Arch Therapeutics.

Has Arch Therapeutics been receiving favorable news coverage?

Media stories about ARTH stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arch Therapeutics earned a media sentiment score of -2.8 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutArch Therapeutics.

Who are some of Arch Therapeutics' key competitors?

What other stocks do shareholders of Arch Therapeutics own?

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the following people:
  • Dr. Terrence W. Norchi, Chairman, Pres, CEO, Sec. & Director (Age 54)
  • Mr. Richard E. Davis, CFO & Treasurer (Age 61)
  • Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)
  • Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific Advisor
  • Dr. Steven A. Kates Ph.D., VP of Technology

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.20.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $37.29 million. Arch Therapeutics employs 8 workers across the globe.

What is Arch Therapeutics' official website?

The official website for Arch Therapeutics is www.archtherapeutics.com.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.